Misoprostol for the Treatment of Incomplete Abortion

NCT00670761 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 720

Last updated 2016-07-27

No results posted yet for this study

Summary

This randomized study will examine the efficacy, safety and acceptability of misoprostol for treatment of incomplete abortion.

Women diagnosed with incomplete abortion will be randomized to receive one of the following regimens:

In Tanzania and Mozambique:

1. 600 mcg of oral misoprostol in one dose, or
2. Standard surgical treatment (MVA)

In Moldova and Madagascar:

1. 600 mcg of oral misoprostol in one dose, or
2. 400 mcg of sublingual misoprostol in one dose.

In Burkina Faso and Vietnam:

1\. 400 mcg of sublingual misoprostol in one dose.

We hypothesize that treatment of incomplete abortion with either 400 mcg sublingual misoprostol, 600 mcg oral misoprostol or MVA are equally effective in evacuating the uterus.

Conditions

  • Abortion, Incomplete

Interventions

DRUG

misoprostol

comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)

PROCEDURE

MVA

comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)

Sponsors & Collaborators

  • Befelatanana Maternity Centre

    collaborator UNKNOWN
  • Municipal Clinical Hospital No. 1

    collaborator UNKNOWN
  • Kagera Regional Hospital

    collaborator OTHER
  • Jose Macamo Hospital

    collaborator UNKNOWN
  • Tudu hospital

    collaborator UNKNOWN
  • National OBGYN hospital

    collaborator UNKNOWN
  • Cuchi General District hospital

    collaborator UNKNOWN
  • Hôpital de District Sanitaire Dandé

    collaborator UNKNOWN
  • Hôpital de District Sanitaire de Ziniaré

    collaborator UNKNOWN
  • Gynuity Health Projects

    lead OTHER

Principal Investigators

  • Beverly Winikoff, MD, MPH · Gynuity Health Projects

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2010-04-30
Completion
2010-12-31

Countries

  • Burkina Faso
  • Madagascar
  • Moldova
  • Mozambique
  • Tanzania

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00670761 on ClinicalTrials.gov